Abstract
BackgroundVitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease.MethodsAn open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen.ResultsThere were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups.ConclusionsWe did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge.Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020
Highlights
Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity
In a clinical study of the role of ascorbic acid against Epstein–Barr virus (EBV) infection showed the EBV IgG and IgM antibody levels reduced during IV vitamin C therapy [12]
Given the positive effect of IV vitamin C for viralinduced acute respiratory distress syndrome (ARDS) and its role for enhancing the function of immune system, we aimed to investigate the correlation of the high-dose intravenous vitamin C (HDIVC) administration with improvement of 2019-nCoV-induced ARDS
Summary
Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. We aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. Ascorbic acid or ascorbate (vitamin C) is an essential water-soluble nutrient that functions as a key antioxidant and is involved in the synthesis of collagen and JamaliMoghadamSiahkali et al Eur J Med Res (2021) 26:20 neurotransmitters, and affects wound healing, energy metabolism, nervous system function, and immune cell health [1,2,3]. In a case report of enterovirus/rhinovirus-induced acute respiratory distress syndrome (ARDS) in 2017, infusion of high-dose IV vitamin C (HDIVC) was associated with rapid resolution of lung injury [13]. A meta-analysis reported the impact of vitamin C on decreasing the duration of intensive care unit (ICU) admission and mechanical ventilation care in patients with ARDS [18,19,20]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
